Risk factors for blood transfusion and its prognostic implications in curative gastrectomy for gastric cancer

Table 5 Univariate and multivariate analyses of factors associated with disease-free and overall survival

	Univariate			Multivariate
	HR	95%CI	P value	HR	95%CI	P value
Disease-free survival
Male vs female	1.27	0.99-1.62	0.051
Age ≥ 65 yr vs < 65 yr	1.25	0.99-1.57	0.059
Charlson ≥ 1 vs 0	1.33	1.05-1.68	0.018	1.22	0.93-1.60	0.159
ASA III/IV vs I/II	1.83	1.44-2.33	< 0.001	1.24	0.93-1.66	0.149
Total gastrectomy vs distal	1.77	1.41-2.33	< 0.001	1.45	1.14-1.84	0.002
D1 vs D2	1.61	1.25-2.07	< 0.001	1.4	1.06-1.85	0.017
pT3/T4 vs pT1/T2	2.87	2.19-3.76	< 0.001	2.05	1.50-2.79	< 0.001
pN+ vs pN0	2.81	2.17-3.65	< 0.001	1.97	1.47-2.65	< 0.001
Major POC vs non/minor POC	2.86	2.19-3.73	< 0.001	2.15	1.62-2.86	< 0.001
Non-CMT vs received CMT	1	0.79-1.26	0.995
Perioperative RBC transfusion vs non	2.39	1.88-3.02	< 0.001	1.49	1.14-1.94	0.003
Overall survival
Male vs female	1.25	0.97-1.61	0.084
Age ≥ 65 yr vs < 65 yr	1.41	1.11-1.80	0.006	1.24	0.95-1.61	0.113
Charlson ≥ 1 vs 0	1.35	1.06-1.73	0.017	1.11	0.83-1.49	0.473
ASA III/IV vs I/II	2.02	1.57-2.61	< 0.001	1.36	1.01-1.85	0.048
Total gastrectomy vs distal	1.65	1.29-2.10	< 0.001	1.33	1.03-1.71	0.027
Lymphadenectomy D1 vs D2	1.81	1.39-2.35	< 0.001	1.51	1.11-2.05	0.008
pT3/T4 vs pT1/T2	2.92	2.19-3.90	< 0.001	2.19	1.57-3.06	< 0.001
pN+ vs pN0	2.7	2.06-3.56	< 0.001	1.87	1.37-2.56	< 0.001
Major POC vs non/minor POC	3.33	2.53-4.38	< 0.001	2.65	1.97-3.56	< 0.001
Non-CMT vs received CMT	1.05	0.83-1.34	0.678
Perioperative RBC transfusion vs non	2.33	1.81-2.99	< 0.001	1.34	1.02-1.77	0.038

ASA: American Society of Anesthesiologists; HR: Hazard ratio; POC: Postoperative complications; CMT: Chemotherapy; RBC: Red blood cell.